A5082539415- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Growth Hormone and Insulin-like Growth Factors
- Pituitary Gland Disorders and Treatments
- Adrenal and Paraganglionic Tumors
- Neutropenia and Cancer Infections
- Diabetes Treatment and Management
- Pharmacy and Medical Practices
- Synthesis and bioactivity of alkaloids
- Pharmaceutical Practices and Patient Outcomes
- Medical Imaging Techniques and Applications
- Medication Adherence and Compliance
- Pharmaceutical studies and practices
- Glycogen Storage Diseases and Myoclonus
- Head and Neck Cancer Studies
- Advanced MRI Techniques and Applications
Novartis (France)
2020-2022
Universidade Estadual de Campinas (UNICAMP)
2021
Novartis (Switzerland)
2017
Institut Gustave Roussy
1997-2004
Centre Léon Bérard
2003
Institut Curie
2003
Laboratoire d'études sur les monothéismes
2000
Centre National de la Recherche Scientifique
1997-1998
A phase I study was performed to determine the maximum-tolerated dose (MTD) and safety profile of irinotecan (CPT-11) administered as a single intravenous infusion every 3 weeks in children with recurrent or refractory solid tumors.Eighty-one patients were enrolled, including 48 less heavily, 33 heavily pretreated (cranial irradiation and/or high-dose chemotherapy). Children received CPT-11 120-minute at doses ranging from 200 720 mg/m2. The dose-limiting toxicities (DLT) on first cycle...
Abstract Context Somatostatin receptor ligands (SRLs) are the cornerstone medical treatments for acromegaly; however, many patients remain unresponsive to SRLs. Well-established predictive markers of response needed. Objective We aimed explore relationship between responsiveness SRLs relative somatostatin (SST)2A and 5 expression, adenoma granularity, T2-weighted magnetic resonance imaging (MRI) signal intensity (T2WSI). Methods conducted a multicentric, prospective, observational cohort...
The anti-tumor activity of irinotecan (CPT-11), a DNA-topoisomerase I inhibitor, was evaluated in 5 advanced stage subcutaneous medulloblastoma xenografts nude mice, using different schedules administration. With 5-day schedule, the highest i.v. dose tested (40 mg kg−1 day−1) induced complete regressions all but 1, and delays tumor growth always exceeded 30 days. Two xenografts, IGRM11 IGRM33, were highly sensitive, animals survived tumor-free beyond 120 days after treatment. CPT-11 clearly...
Abstract Topoisomerase I inhibitors, such as CPT-11, are potent anticancer drugs against neuroblastoma (NB). Differentiating agents, retinoids, improve the survival of children with metastatic NB. To characterize biological effects associated exposure to CPT-11 in vivo, athymic mice bearing a human NB xenograft, named IGR-NB8 and characterized an immature poor prognostic markers, were treated CPT-11. Prolonged stable disease was observed, resulting overall tumor growth delay 115 days. During...
Approval of sunitinib and everolimus for the treatment progressive, unresectable or metastatic well-differentiated pancreatic neuroendocrine tumors (pNETs) was obtained in France 2011 2012, respectively. OPALINE set up as an observational study to evaluate efficacy compared usual pNET treatments chemotherapies somatostatin analogues that had been previously recommended by health authorities.The assessed terms survival, disease progression tolerance. Patients (N = 144) were enrolled from May...
CPT-11 (irinotecan) is a DNA-topoisomerase I inhibitor with preclinical activity against neuroblastoma (NB) xenografts. The aim was to establish in vivo an NB xenograft resistant order study the resistance mechanisms acquired therapeutic setting. IGR-NB8 immature MYCN amplification and 1p deletion, which sensitive CPT-11. Athymic mice bearing advanced-stage subcutaneous tumours were treated (27 mg kg(-1) day(-1) x 5) every 21 days (1 cycle) for maximum of four cycles. After tumour regrowth,...
Background: There is a lack of knowledge regarding the experience patients with neuroendocrine tumors (NET) in France. Materials & methods: A patient survey that captured information on diagnosis, disease impact/management and awareness was conducted. Data respondents from France were analyzed compared US data as reference. Results: Key topics included delays negative impact quality life, access to NET medical experts treatments, treatments. Significant differences observed between USA...
The anti-tumor activity of irinotecan (CPT-11), a DNA-topoisomerase I inhibitor, was evaluated in 5 advanced stage subcutaneous medulloblastoma xenografts nude mice, using different schedules administration. With 5-day schedule, the highest i.v. dose tested (40 mg kg−1 day−1) induced complete regressions all but 1, and delays tumor growth always exceeded 30 days. Two xenografts, IGRM11 IGRM33, were highly sensitive, animals survived tumor-free beyond 120 days after treatment. CPT-11 clearly...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)